Exelixis
EXEL
#1643
Rank
C$14.96 B
Marketcap
$52.41
Share price
-0.96%
Change (1 day)
72.20%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): $0.38

According to Exelixis's latest financial reports the company's current EPS (TTM) is $0.41. In 2022 the company made an earnings per share (EPS) of $0.83 a decrease over its 2021 EPS that were of $1.07.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$0.38-54.45%
2022$0.83-22.97%
2021$1.07100%
2020$0.54-65.09%
2019$1.53-53.91%
2018$3.33333.96%
2017$0.77-260.61%
2016-$0.48-58.75%
2015-$1.16-42.45%
2014-$2.015.3%
2013-$1.9143.48%
2012-$1.33-264.29%
2011$0.81-165.88%
2010-$1.23-32.54%
2009-$1.82-17.65%
2008-$2.2275.86%
2007-$1.26-25.64%
2006-$1.698.33%
2005-$1.56-42.86%
2004-$2.7430.34%
2003-$2.10-5.23%
2002-$2.22-0.65%
2001-$2.23-51.88%
2000-$4.63

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$5.07 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
$4.60 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
$2.64 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.75 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
$20.49 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
$20.39 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
$2.69 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-$14.48-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-$1.22-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA